Serina Therapeutics secured up to $30.0M via definitive agreements for a private placement of common stock and pre-funded warrants. The cash is earmarked to support the registrational trial of SER-252 in advanced Parkinson's disease, reducing near-term funding risk and modestly improving the company's development outlook.
Serina Therapeutics secured up to $30.0M via definitive agreements for a private placement of common stock and pre-funded warrants. The cash is earmarked to support the registrational trial of SER-252 in advanced Parkinson's disease, reducing near-term funding risk and modestly improving the company's development outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
